ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

belvarafenib

Also written as “Belvarafenib”, “HM95573, cobimetinib” and “HM95573, cetuximab”.

Its studies are mostly in Melanoma · Neoplasm Metastasis · Neoplasms, led by 2 companies.

Drug pageBelvarafenib: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Feb 27, 20266 company-led studies, 4 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hanmi Pharmaceuticalits history only42 open or runningphase 2since Feb 27, 2026Jan 15, 2015Sep 2029phase 2 · NCT07449754
Hoffmann-La Roche22 open or runningphase 2since Oct 11, 2020Oct 11, 2020Dec 31, 2026phase 1 · NCT04835805

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2017Named belvarafenibINNProposed as its International Nonproprietary Name in WHO's List 118 · before, HM95573
  2. Oct 11, 2020First study: phase 2 study in Solid TumorsFirst studyNCT04589845 · 920 enrolled · United States, Australia, Belgium and more
  3. Apr 6, 2021Phase 1 study in MelanomaNCT04835805 · 65 enrolled · United States, Australia, Canada and more

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in MelanomaNCT04835805
  2. Sep 25, 2032Primary completion: phase 2 study in Solid TumorsNCT04589845

TargetBeta

“RAF serine/threonine protein kinase inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
tovorafenibruleday-one-biopharmaceuticals-incphase 38

Studies

All 2 Hoffmann-La Roche leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04835805Melanoma · United States, Australia, Canada and more1Active, not recruitingDec 31, 202665
NCT04589845Solid Tumors · United States, Australia, Belgium and more2Active, not recruitingSep 25, 2032920

How it is read

Names in the registry

  • “Belvarafenib”, 3 entries
  • “HM95573, cobimetinib”, 2 entries
  • “HM95573, cetuximab”, 2 entries
  • “HM95573”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.